MedTrace Logo

Prostatic Hyperplasia Treatment and Cancer Prevention

NCT03064282 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-25

No results posted yet for this study

Summary

Treatment of patients with prostatic hyperplasia with topical papaverine.

Conditions

  • Prostatic Hyperplasia

Interventions

OTHER

Placebo

observation of skin changes if any

DRUG

papaverine

observation of symptoms

Sponsors & Collaborators

  • Manchanda Medical Clinic

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2021-09-30
Completion
2021-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03064282 on ClinicalTrials.gov